Loading clinical trials...

PTEN-AKT-FOXO3 Gene Expression Relation With Low-ovarian Reserve in Endometriomas | Clinical Trials | Clareo Health

UNKNOWNNCT04058912

PTEN-AKT-FOXO3 Gene Expression Relation With Low-ovarian Reserve in Endometriomas

In this study, we aimed to investigate the relationship between PTEN-AKT-FOXO3 gene expression and decrease in ovarian reserve in the presence of endometrioma and other benign ovarian pathologies.

Lead sponsor: Uludag University•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

HAMZA F SEN, MD

CONTACT

+90 544 3939159 hamzafurkansen@yahoo.com

Isil Kasapoglu, MD

CONTACT

+905305455848 kasapogluisil@hotmail.com

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment60

Start dateMay 2019

Last updatedAug 16, 2019

Locations shown

Uludag University Hospital, Department of Obstetrics and Gynecology

Bursa, Nilufer

Uludag University Hospital, Department of Obstetrics and Gynecology

Bursa, Nilufer

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 16, 2019Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions